These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19815660)

  • 1. Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy.
    Franz M; Berndt A; Altendorf-Hofmann A; Fiedler N; Richter P; Schumm J; Fritzenwanger M; Figulla HR; Brehm BR
    Eur J Heart Fail; 2009 Nov; 11(11):1057-62. PubMed ID: 19815660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels.
    Hessel MH; Bleeker GB; Bax JJ; Henneman MM; den Adel B; Klok M; Schalij MJ; Atsma DE; van der Laarse A
    Eur J Heart Fail; 2007 Oct; 9(10):1058-63. PubMed ID: 17728181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
    Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma TIMP-4 predicts left ventricular remodeling after acute myocardial infarction.
    Weir RA; Clements S; Steedman T; Dargie HJ; McMurray JJ; Squire IB; Ng LL
    J Card Fail; 2011 Jun; 17(6):465-71. PubMed ID: 21624734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
    Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
    Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variations with time of plasma concentrations of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2.
    Rossignol P; Jacob MP; Cambillau M; Mouradian D; Plouin PF; Chatellier G
    Thromb Res; 2007; 119(2):261-3. PubMed ID: 16530811
    [No Abstract]   [Full Text] [Related]  

  • 8. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
    Yang YJ; Zhang X; Zhu WL; Huang Y
    Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating matrix metalloproteinases and their inhibitors in inguinal hernia and abdominal aortic aneurysm.
    Antoniou GA; Tentes IK; Antoniou SA; Georgiadis GS; Giannoukas AD; Simopoulos C; Lazarides MK
    Int Angiol; 2011 Apr; 30(2):123-9. PubMed ID: 21427648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of plasma tissue inhibitors of metalloproteinases as markers of prognosis after acute myocardial infarction.
    Kelly D; Squire IB; Khan SQ; Dhillon O; Narayan H; Ng KH; Quinn P; Davies JE; Ng LL
    Am J Cardiol; 2010 Aug; 106(4):477-82. PubMed ID: 20691304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart.
    Heymans S; Schroen B; Vermeersch P; Milting H; Gao F; Kassner A; Gillijns H; Herijgers P; Flameng W; Carmeliet P; Van de Werf F; Pinto YM; Janssens S
    Circulation; 2005 Aug; 112(8):1136-44. PubMed ID: 16103240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip.
    Masuhara K; Nakai T; Yamaguchi K; Yamasaki S; Sasaguri Y
    Arthritis Rheum; 2002 Oct; 46(10):2625-31. PubMed ID: 12384920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression.
    Polyakova V; Hein S; Kostin S; Ziegelhoeffer T; Schaper J
    J Am Coll Cardiol; 2004 Oct; 44(8):1609-18. PubMed ID: 15489093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitant hearts.
    Truter SL; Catanzaro DF; Supino PG; Gupta A; Carter J; Herrold EM; Dumlao TF; Borer JS
    Cardiology; 2009; 113(3):161-8. PubMed ID: 19129699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
    George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
    Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
    Hoffmann U; Bertsch T; Dvortsak E; Liebetrau C; Lang S; Liebe V; Huhle G; Borggrefe M; Brueckmann M
    Scand J Infect Dis; 2006; 38(10):867-72. PubMed ID: 17008230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
    J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of sequential serum measurements of gelatinases and tissue inhibitors during chemotherapy in ovarian cancer.
    Rauvala M; Turpeenniemi-Hujanen T; Puistola U
    Anticancer Res; 2006; 26(6C):4779-84. PubMed ID: 17214341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure.
    Tousoulis D; Andreou I; Tentolouris C; Antoniades C; Papageorgiou N; Gounari P; Kotrogiannis I; Miliou A; Charakida M; Trikas A; Stefanadis C
    Int J Cardiol; 2010 Dec; 145(3):438-43. PubMed ID: 19539384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.